In The NEWS

Alzheimer's disease

Early Clinical Development of Synapse-Focused Agent SPG302 for Alzheimer Disease

Sydney Alzheimer’s Patients Will Be The First to Trial a New Drug

Hope Pill Will Turn Tables on Dementia

Synapse-regenerating drug could reverse decline in Alzheimer’s

amyotrophic lateral sclerosis (ALS)

FDA Clears Phase 1/2 Clinical Trial for Spinogenix’s ALS Treatment SPG302

Spinogenix Announces FDA Clearance of IND Application Novel Therapy for the Treatment of ALS

World-first MND drug trial offers hope to those living with the disorder

FDA OKs Phase 1/2 clinical trial of small molecule SPG302 in ALS

FDA clears investigational new drug application for clinical trial of ALS pill

Synapse-Generating Small Molecule for ALS Receives Nod from FDA for Clinical Trial

FDA grants IND clearance for Spinogenix’s ALS treatment trial

Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials

Spinogenix’s Daily Pill SPG302 Receives FDA IND Nod for ALS Treatment

A Promising Treatment for MND

A new drug that could reverse the worst symptoms of MND is about to be trialled in Australia.

Novel motor neurone disease, MND, drug SPG302 to be trialled in Australia

ALS ONE Research Symposium – Presentation by Peter Vanderklish, PhD of Spinogenix

Spinogenix Lands $4M in New Federal Grants

Spinogenix awarded $1M to advance clinical testing of SPG302

Spinogenix: World-first trial giving hope to those living with MND

Clinical trial of oral ALS therapy SPG302 is enrolling in Australia | ALS News Today

Human Trial Gives Hope to MND Patients

Australians with MND will be the first in the world to trial a new drug

World first drug trial for MND treatment | Sky News Australia

A world-first trial for a new drug that may slow the progression of motor neurone disease is set to begin in Melbourne.

World first drug trial for MND treatment | The Australian

World first drug trial for MND treatment